ANDREWS DEBORAH J 4
4 · Lineage Cell Therapeutics, Inc. · Filed Jun 30, 2021
Insider Transaction Report
Form 4
ANDREWS DEBORAH J
Director
Transactions
- Sale
Common Shares, no par value
2021-06-29$2.93/sh−19,142$56,086→ 15,578 total - Exercise/Conversion
Common Shares, no par value
2021-06-29$2.20/sh+24,720$54,384→ 34,720 total - Exercise/Conversion
Stock Option (right to buy)
2021-06-29−24,720→ 0 totalExercise: $2.20Exp: 2021-06-30→ Common Shares (24,720 underlying)
Footnotes (2)
- [F1]The price reported is a weighted average. These shares were sold in multiple transactions at a price of $2.93 or $2.935. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- [F2]This option became exercisable in four equal quarterly installments after the date of grant on July 1, 2016